Xifaxan Alternatives Compared
| Xifaxan (rifaximin) | Viberzi (eluxadoline) | Lotronex (alosetron) |
|
|---|
| Xifaxan (rifaximin) | Viberzi (eluxadoline) | Lotronex (alosetron) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hepatic Encephalopathy, Irritable Bowel Syndrome with Diarrhea, Irritable Bowel Syndrome, Traveler's Diarrhea, Diarrhea. Xifaxan may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Irritable Bowel Syndrome with Diarrhea, Diarrhea, Irritable Bowel Syndrome. Viberzi may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Irritable Bowel Syndrome with Diarrhea, Diarrhea, Irritable Bowel Syndrome. Lotronex may also be used for purposes not listed in this medication guide. |
Related suggestions Irritable Bowel Syndrome
Irritable Bowel Syndrome with Diarrhea
Popular comparisons
|
|||||||||||||||||||||||
| More about Xifaxan (rifaximin) | More about Viberzi (eluxadoline) | More about Lotronex (alosetron) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Xifaxan has an average rating of 6.6 out of 10 from a total of 97 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 34% reported a negative effect. |
Viberzi has an average rating of 6.7 out of 10 from a total of 217 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 25% reported a negative effect. |
Lotronex has an average rating of 9.6 out of 10 from a total of 24 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Xifaxan side effects |
View all Viberzi side effects |
View all Lotronex side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Xifaxan prices |
View all Viberzi prices |
View all Lotronex prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
10.19 hours |
6 hours |
1.5 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 92 drugs are known to interact with Xifaxan:
|
A total of 214 drugs are known to interact with Viberzi:
|
A total of 99 drugs are known to interact with Lotronex:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 25, 2004 |
May 27, 2015 |
February 09, 2000 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.